Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
45
GALDY Quote, Financials, Valuation and Earnings
Last price:
$37.67
Seasonality move
:
-9.72%
Day range:
$37.49 - $38.29
52-week range:
$17.27 - $42.93
Dividend yield:
0.04%
P/E ratio:
130.29x
P/S ratio:
9.58x
P/B ratio:
4.98x
Volume:
63.3K
Avg. volume:
198.7K
1-year change:
45.74%
Market cap:
$44.3B
Revenue:
$4.4B
EPS (TTM):
$0.32
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GALDY
Galderma Group AG
|
-- | -- | -- | -- | -- |
|
BPMUF
Basilea Pharmaceutica AG
|
$93.1M | -- | -- | -- | -- |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -- | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- |
|
RHHBY
Roche Holding AG
|
$19.8B | -- | -- | -- | $58.80 |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GALDY
Galderma Group AG
|
$37.76 | -- | $44.3B | 130.29x | $0.03 | 0.04% | 9.58x |
|
BPMUF
Basilea Pharmaceutica AG
|
$71.00 | -- | $871.3M | 19.33x | $0.00 | 0% | 3.46x |
|
CSBTF
Kuros Biosciences Ltd.
|
$32.00 | -- | $1.3B | -- | $0.00 | 0% | 9.78x |
|
ELVAF
EvoNext Holdings SA
|
$1.1000 | -- | $7.9M | 5.90x | $0.00 | 0% | 0.61x |
|
RHHBY
Roche Holding AG
|
$59.03 | $58.80 | $376.1B | 24.57x | $1.39 | 2.35% | 5.12x |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
$21.15 | -- | $274.4M | 1.45x | $0.00 | 0% | 4.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GALDY
Galderma Group AG
|
26.02% | 1.432 | -- | 0.80x |
|
BPMUF
Basilea Pharmaceutica AG
|
85.07% | 0.813 | -- | 2.96x |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -0.224 | -- | 1.61x |
|
ELVAF
EvoNext Holdings SA
|
-- | 0.210 | -- | -- |
|
RHHBY
Roche Holding AG
|
53.53% | -0.511 | -- | 0.88x |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
33% | -6.454 | -- | 0.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GALDY
Galderma Group AG
|
-- | -- | 3.62% | 4.9% | -- | -- |
|
BPMUF
Basilea Pharmaceutica AG
|
-- | -- | -0.84% | -15.42% | -- | -- |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -6.35% | -6.35% | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- | -- |
|
RHHBY
Roche Holding AG
|
-- | -- | 14.32% | 28.65% | -- | -- |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
-- | -- | 123.12% | 276.68% | -- | -- |
Galderma Group AG vs. Competitors
-
Which has Higher Returns GALDY or BPMUF?
Basilea Pharmaceutica AG has a net margin of -- compared to Galderma Group AG's net margin of --. Galderma Group AG's return on equity of 4.9% beat Basilea Pharmaceutica AG's return on equity of -15.42%.
Company Gross Margin Earnings Per Share Invested Capital GALDYGalderma Group AG-- -- $10.4B BPMUFBasilea Pharmaceutica AG-- -- $125.1M -
What do Analysts Say About GALDY or BPMUF?
Galderma Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Basilea Pharmaceutica AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Galderma Group AG has higher upside potential than Basilea Pharmaceutica AG, analysts believe Galderma Group AG is more attractive than Basilea Pharmaceutica AG.
Company Buy Ratings Hold Ratings Sell Ratings GALDYGalderma Group AG0 0 0 BPMUFBasilea Pharmaceutica AG0 0 0 -
Is GALDY or BPMUF More Risky?
Galderma Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Basilea Pharmaceutica AG has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.835%.
-
Which is a Better Dividend Stock GALDY or BPMUF?
Galderma Group AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.04%. Basilea Pharmaceutica AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galderma Group AG pays -- of its earnings as a dividend. Basilea Pharmaceutica AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GALDY or BPMUF?
Galderma Group AG quarterly revenues are --, which are smaller than Basilea Pharmaceutica AG quarterly revenues of --. Galderma Group AG's net income of -- is lower than Basilea Pharmaceutica AG's net income of --. Notably, Galderma Group AG's price-to-earnings ratio is 130.29x while Basilea Pharmaceutica AG's PE ratio is 19.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galderma Group AG is 9.58x versus 3.46x for Basilea Pharmaceutica AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALDYGalderma Group AG9.58x 130.29x -- -- BPMUFBasilea Pharmaceutica AG3.46x 19.33x -- --
-
Which has Higher Returns GALDY or CSBTF?
Kuros Biosciences Ltd. has a net margin of -- compared to Galderma Group AG's net margin of --. Galderma Group AG's return on equity of 4.9% beat Kuros Biosciences Ltd.'s return on equity of -6.35%.
Company Gross Margin Earnings Per Share Invested Capital GALDYGalderma Group AG-- -- $10.4B CSBTFKuros Biosciences Ltd.-- -- $65M -
What do Analysts Say About GALDY or CSBTF?
Galderma Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Kuros Biosciences Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Galderma Group AG has higher upside potential than Kuros Biosciences Ltd., analysts believe Galderma Group AG is more attractive than Kuros Biosciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings GALDYGalderma Group AG0 0 0 CSBTFKuros Biosciences Ltd.0 0 0 -
Is GALDY or CSBTF More Risky?
Galderma Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kuros Biosciences Ltd. has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.678%.
-
Which is a Better Dividend Stock GALDY or CSBTF?
Galderma Group AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.04%. Kuros Biosciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galderma Group AG pays -- of its earnings as a dividend. Kuros Biosciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GALDY or CSBTF?
Galderma Group AG quarterly revenues are --, which are smaller than Kuros Biosciences Ltd. quarterly revenues of --. Galderma Group AG's net income of -- is lower than Kuros Biosciences Ltd.'s net income of --. Notably, Galderma Group AG's price-to-earnings ratio is 130.29x while Kuros Biosciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galderma Group AG is 9.58x versus 9.78x for Kuros Biosciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALDYGalderma Group AG9.58x 130.29x -- -- CSBTFKuros Biosciences Ltd.9.78x -- -- --
-
Which has Higher Returns GALDY or ELVAF?
EvoNext Holdings SA has a net margin of -- compared to Galderma Group AG's net margin of --. Galderma Group AG's return on equity of 4.9% beat EvoNext Holdings SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GALDYGalderma Group AG-- -- $10.4B ELVAFEvoNext Holdings SA-- -- -- -
What do Analysts Say About GALDY or ELVAF?
Galderma Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand EvoNext Holdings SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Galderma Group AG has higher upside potential than EvoNext Holdings SA, analysts believe Galderma Group AG is more attractive than EvoNext Holdings SA.
Company Buy Ratings Hold Ratings Sell Ratings GALDYGalderma Group AG0 0 0 ELVAFEvoNext Holdings SA0 0 0 -
Is GALDY or ELVAF More Risky?
Galderma Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison EvoNext Holdings SA has a beta of -42.013, suggesting its less volatile than the S&P 500 by 4301.301%.
-
Which is a Better Dividend Stock GALDY or ELVAF?
Galderma Group AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.04%. EvoNext Holdings SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galderma Group AG pays -- of its earnings as a dividend. EvoNext Holdings SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GALDY or ELVAF?
Galderma Group AG quarterly revenues are --, which are smaller than EvoNext Holdings SA quarterly revenues of --. Galderma Group AG's net income of -- is lower than EvoNext Holdings SA's net income of --. Notably, Galderma Group AG's price-to-earnings ratio is 130.29x while EvoNext Holdings SA's PE ratio is 5.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galderma Group AG is 9.58x versus 0.61x for EvoNext Holdings SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALDYGalderma Group AG9.58x 130.29x -- -- ELVAFEvoNext Holdings SA0.61x 5.90x -- --
-
Which has Higher Returns GALDY or RHHBY?
Roche Holding AG has a net margin of -- compared to Galderma Group AG's net margin of --. Galderma Group AG's return on equity of 4.9% beat Roche Holding AG's return on equity of 28.65%.
Company Gross Margin Earnings Per Share Invested Capital GALDYGalderma Group AG-- -- $10.4B RHHBYRoche Holding AG-- -- $82.8B -
What do Analysts Say About GALDY or RHHBY?
Galderma Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Roche Holding AG has an analysts' consensus of $58.80 which suggests that it could fall by -0.39%. Given that Roche Holding AG has higher upside potential than Galderma Group AG, analysts believe Roche Holding AG is more attractive than Galderma Group AG.
Company Buy Ratings Hold Ratings Sell Ratings GALDYGalderma Group AG0 0 0 RHHBYRoche Holding AG2 4 1 -
Is GALDY or RHHBY More Risky?
Galderma Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.440, suggesting its less volatile than the S&P 500 by 56.044%.
-
Which is a Better Dividend Stock GALDY or RHHBY?
Galderma Group AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.04%. Roche Holding AG offers a yield of 2.35% to investors and pays a quarterly dividend of $1.39 per share. Galderma Group AG pays -- of its earnings as a dividend. Roche Holding AG pays out 58.07% of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GALDY or RHHBY?
Galderma Group AG quarterly revenues are --, which are smaller than Roche Holding AG quarterly revenues of --. Galderma Group AG's net income of -- is lower than Roche Holding AG's net income of --. Notably, Galderma Group AG's price-to-earnings ratio is 130.29x while Roche Holding AG's PE ratio is 24.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galderma Group AG is 9.58x versus 5.12x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALDYGalderma Group AG9.58x 130.29x -- -- RHHBYRoche Holding AG5.12x 24.57x -- --
-
Which has Higher Returns GALDY or SPHDF?
Santhera Pharmaceuticals Holding AG has a net margin of -- compared to Galderma Group AG's net margin of --. Galderma Group AG's return on equity of 4.9% beat Santhera Pharmaceuticals Holding AG's return on equity of 276.68%.
Company Gross Margin Earnings Per Share Invested Capital GALDYGalderma Group AG-- -- $10.4B SPHDFSanthera Pharmaceuticals Holding AG-- -- $79.8M -
What do Analysts Say About GALDY or SPHDF?
Galderma Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Santhera Pharmaceuticals Holding AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Galderma Group AG has higher upside potential than Santhera Pharmaceuticals Holding AG, analysts believe Galderma Group AG is more attractive than Santhera Pharmaceuticals Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings GALDYGalderma Group AG0 0 0 SPHDFSanthera Pharmaceuticals Holding AG0 0 0 -
Is GALDY or SPHDF More Risky?
Galderma Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Santhera Pharmaceuticals Holding AG has a beta of -0.796, suggesting its less volatile than the S&P 500 by 179.584%.
-
Which is a Better Dividend Stock GALDY or SPHDF?
Galderma Group AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.04%. Santhera Pharmaceuticals Holding AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galderma Group AG pays -- of its earnings as a dividend. Santhera Pharmaceuticals Holding AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GALDY or SPHDF?
Galderma Group AG quarterly revenues are --, which are smaller than Santhera Pharmaceuticals Holding AG quarterly revenues of --. Galderma Group AG's net income of -- is lower than Santhera Pharmaceuticals Holding AG's net income of --. Notably, Galderma Group AG's price-to-earnings ratio is 130.29x while Santhera Pharmaceuticals Holding AG's PE ratio is 1.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galderma Group AG is 9.58x versus 4.78x for Santhera Pharmaceuticals Holding AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GALDYGalderma Group AG9.58x 130.29x -- -- SPHDFSanthera Pharmaceuticals Holding AG4.78x 1.45x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 15.01% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 7.02% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 5.48% over the past day.
